A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2013
At a glance
- Drugs Mapatumumab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 05 Mar 2012 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
- 21 Nov 2009 Actual initiation date (28 Jun 2004) and patient number (14) added as reported by M.D. Anderson Cancer Center record.
- 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2004-0087).